Podcast | The Practice of Medicine | April 12, 2021

Safety of Baricitinib 4 mg for the Treatment of Rheumatoid Arthritis

Join Drs. Tracey Dabal and Christopher Jackson as they discuss the safety of baricitinib for the treatment of rheumatoid arthritis, a topic they address in their article that will appear in the May 2021 issue of the Southern Medical Journal. In this podcast, they talk about why they chose to perform their safety-focused meta-analysis and what results were the most surprising to them. They also provide insight into how the findings could impact practice. Additionally, the two of them share their perspective on submitting and having published a research article, as well as touch on the various aspects involved with the publication process.

Dr. Tracey Dabal is the chief resident of ambulatory medicine with the University of Tennessee Health Science Center internal medicine residency program. She is originally from New Jersey where she studied Biochemistry at Montclair State University. Dr. Dabal subsequently completed her medical school training at Ross University School of Medicine. She has a special interest in ambulatory education and curriculum design.

 

Dr. Chris Jackson serves as an Assistant Professor of Medicine and Associate Program Director of the Internal Medicine Residency Program at the University of Tennessee Health Science Center (UTHSC). A native of Augusta, GA, he studied Biology and Sociology at Emory University and received his Doctor of Medicine degree at the Medical College of Georgia. He completed his residency and a year as Chief Medical Resident residency at UTHSC where he joined the faculty in the Division of General Internal Medicine and the Center for Health System Improvement in 2019. Dr. Jackson’s research interests focus on evaluating educational and quality improvement efforts to improve primary care practice, patient-centered health outcomes, and delivery of evidence-based medicine.

Disclosure Information
Drs. Dabal and Jackson do not have any financial relationships or conflicts of interest.

References and Resources

  1. Dabal TD, Halton MB, Patel PP, et al. Safety of baricitinib for 4 mg for the treatment of moderate to severe rheumatoid arthritis. South Med J 2021. In Press.
  2. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
  3. Keystone EC, Genovese MC, Schlichting DE, et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. J Rheumatol 2018;45:14–21.
  4. Eli Lilly and Company. FDA Briefing Document. Arthritis Advisory Committee Meeting, April 23, 2018. NDA 207924, Baricitinib Janus Kinase (JAK) inhibitor for RA. https://www.fda.gov/media/112372/download. Published 2018. Accessed February 28, 2021.
  5. Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755–1766.